LIPC
LIPC (lipase C, hepatic type), also known as HL or HTGL, is a secreted lipase that hydrolyses triglycerides and phospholipids in circulating plasma lipoproteins. It remodels lipoprotein particles and releases free fatty acids, and it is a member of the lipase gene group. Browse Assay Genie's current range of LIPC research reagents below, or read on for the biology behind the target.
LIPC catalyses the hydrolysis of triglycerides and phospholipids present in circulating plasma lipoproteins. Its substrates include chylomicrons, intermediate density lipoproteins (IDL), large low density lipoproteins (LDL) and high density lipoproteins (HDL). Hydrolysis releases free fatty acids (FFA) and leaves smaller lipoprotein particles. The enzyme also has lysophospholipase activity, and it can act on both neutral lipid and phospholipid substrates, although it binds neutral lipid substrates with greater affinity. In native LDL, it preferentially hydrolyses phosphatidylcholine species that carry polyunsaturated fatty acids at the sn-2 position.
The LIPC gene encodes hepatic triacylglycerol lipase, a secreted protein that belongs to the lipase family within the AB hydrolase superfamily. NCBI Gene annotates it with glycerophospholipid phospholipase A1 activity and triacylglycerol lipase activity. It is involved in cholesterol homeostasis, plasma lipoprotein particle remodelling and the triglyceride catabolic process. The protein is classed under EC 3.1.1.3, and orthologous genes are named Lipc in mouse and rat.
The enzyme was formerly listed as lipase, hepatic, and the abbreviations HL and HTGL remain in common use. Variation in this gene is implicated in several diseases, including Alzheimer's disease, coronary artery disease, familial combined hyperlipidaemia, peripheral vascular disease and type 2 diabetes mellitus. LIPC is also described as a biomarker of hyperinsulinism, obesity and type 1 diabetes mellitus, which makes the LIPC protein a frequent subject in lipid and metabolic research.
LIPC hydrolyses triglycerides and phospholipids in chylomicrons, IDL, LDL and HDL, so it is central to studies of plasma lipoprotein remodelling.
The enzyme is involved in cholesterol homeostasis and triglyceride catabolism, making it a relevant target in lipid regulation research.
LIPC is implicated in coronary artery disease, peripheral vascular disease and familial combined hyperlipidaemia.
LIPC is implicated in type 2 diabetes and is a biomarker of hyperinsulinism, obesity and type 1 diabetes mellitus.
LIPC hydrolyses triglycerides and phospholipids in circulating lipoproteins, including chylomicrons, IDL, LDL and HDL. This releases free fatty acids and produces smaller lipoprotein particles. It also has lysophospholipase activity and binds neutral lipid substrates more strongly than phospholipids.
LIPC stands for lipase C, hepatic type. Its aliases are HL and HTGL, the UniProt name is hepatic triacylglycerol lipase, and an earlier HGNC name was lipase, hepatic. It is classed as EC 3.1.1.3 and belongs to the lipase gene group.
Mouse and rat both have an ortholog named Lipc; check the datasheet of any product for its validated reactivity. In humans, LIPC is implicated in Alzheimer's disease, coronary artery disease, familial combined hyperlipidaemia, peripheral vascular disease and type 2 diabetes mellitus.
Other lipases, apolipoproteins and lipoprotein metabolism targets with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt P11150; product specifications from Assay Genie datasheets.